Grady Grant III
Known title: DirectorCIK: 0001679966
Grady Grant III's purchase track record
Grady Grant III has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/10/2025 | APVO | $20K | -75.4% | -82.8% | +8.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| APVO | ▲ Buy | Option Exercise | 400 | — | 8/6/2026 | View on chart |
| APVO | ▲ Buy | Open Market | 13,513 | $20K | 11/10/2025 | View on chart |
| APVO | ▲ Buy | Option Exercise | 1 | — | 7/17/2025 | View on chart |
| APVO | ▲ Buy | Option Exercise | 81 | — | 6/2/2024 | View on chart |
| APVO | ▲ Buy | Option Exercise | 7 | — | 6/1/2024 | View on chart |
| APVO | ▲ Buy | Option Exercise | 3,571 | — | 8/9/2023 | View on chart |
| APVO | ▲ Buy | Option Exercise | 297 | — | 6/1/2023 | View on chart |
| APVO | ▲ Buy | Option Exercise | 298 | — | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
APVO to Present Multispecific Platform at SITC 2026 Meeting
Aptevo Therapeutics announced it will showcase its multispecific antibody platform at the upcoming SITC 2026 Annual Meeting. The presentation offers the company a chance to highlight its pipeline to a specialized oncology audience. The stock is currently near a support level and has a relatively low RSI, which may reflect recent price pressure.
APVO to Present Multispecific Platform at SITC 2026 Meeting. Aptevo Therapeutics announced it will showcase its multispecific antibody platform at the upcoming SITC 2026 Annual Meeting. The presentation offers the company a chance to highlight its pipeline to a specialized oncology audience. The stock is currently near a support level and has a relatively low RSI, which may reflect recent price pressure.